Recruiting NCT04952272 Last updated by the registry: 2024-06-26

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

Phase I Interventional Lung Cancer Hepatocellular Carcinoma Solid Tumor

Why this appeared in your results: Lung Cancer, Hepatocellular Carcinoma · Recruiting · China · Phase I

Detailed eligibility, including treatment history and laboratory results, still needs to be checked.

For patients and families

In plain language

Ask a coordinator

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CpG-ODN.
Who it may be relevant to
Registry conditions: Lung Cancer, Hepatocellular Carcinoma, Solid Tumor. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Check whether this may suit me

This is a preliminary orientation based on public registry fields, not a confirmation of eligibility. Nothing you enter here is sent anywhere — it stays in your browser.

Unsure about the terms? Read our patient guide →

Official title

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors

Overview

To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.

Detailed description

1. Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens 2. Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40 3. Assessing side effects and therapeutic efficacy after the combined treatments

Interventions

  • Combination product CpG-ODN
    CAR-T cells secreting scFv against OX40

Primary outcome measures

  • Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors [Time frame: up to 36 months]

Eligibility criteria

Inclusion criteria

  • Solid advanced malignant tumors
  • Age between18 and 80 years
  • Life expectancy is greater than three months

Exclusion criteria

  • Benign tumor
  • Life expectancy is less than three months
  • Serious medical comorbidity
  • Others

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Questions to ask your doctor

  • Is this trial appropriate for my diagnosis and stage?
  • What is known about the study treatment and its risks?
  • Would participation interfere with my current treatment?
  • Which tests are needed to check the eligibility criteria?
  • Are there similar trials closer to home?

What information a coordinator may need

  • the exact diagnosis and stage (briefly, as in the medical report);
  • previous and current treatment with dates;
  • recent tests and reports (CT/MRI/PET, pathology) — when the coordinator asks, not in the first request;
  • age, country of residence and ability to travel;
  • the NCT number of this trial (filled in automatically when you apply from this page).

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • The Second Affiliated Hospital of Guangzhou Medical University — Guangzhou

Identifiers

NCT: NCT04952272 · ZZITCpG-013

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗

Ask a coordinator